The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation.
Contact phone
Sparrow Clinical Research Institute | 517.364.5760
Contact email
[email protected]
Principal investigator
Dr. Ali Sheikh, DO
Trial Category
Heart & Vascular
Trial SubCategory
Atrial Fibrillation
Webform